Becton, Dickinson and Company ($BDX) $175 Million SEC Fair Fund
The SEC established a $175 million Fair Fund for investors harmed by Becton Dickinson’s misleading statements about regulatory and safety risks affecting its Alaris infusion pump and its improper accounting for remediation costs.
Outline:
Becton Dickinson sold its Alaris infusion pump while dealing with significant software and regulatory issues. The SEC found that BD did not adequately disclose the risk that FDA requirements could prevent continued sales of the product. BD also overstated its financial results by failing to properly account for remediation costs. BD paid a $175 million civil penalty that is now being distributed to harmed investors through an SEC Fair Fund.
Timeline:
October 31, 2019: The FDA rejected BD’s proposed approach for Alaris and warned that the device had defects and safety issues that needed to be addressed.
November 5, 2019: BD told investors that Alaris shipments were being delayed for software improvements while maintaining financial forecasts that assumed most lost sales would be recovered later in the year.
November 27, 2019: BD filed its annual report without recording approximately $59 million in estimated Alaris remediation costs, which the SEC found overstated the company’s financial results.
January 14, 2020: BD told investors that Alaris shipments had resumed and reaffirmed its 2020 revenue guidance.
January 23, 2020: BD again stopped shipping Alaris after the FDA raised concerns about the company resuming sales without addressing significant safety issues.
February 6, 2020: BD disclosed that it needed new FDA clearance for Alaris and would stop selling the device to new customers until approval was obtained; BDX shares fell about 12%.
December 16, 2024: The SEC ordered BD to pay a $175 million civil penalty and established a Fair Fund for harmed investors.
Background:
Becton Dickinson’s Alaris infusion pump was an important product for the company, contributing approximately 10% of its profits. From 2016 through early 2020, BD became aware that Alaris required additional FDA clearance to address historical changes to the device and multiple software problems that posed potential safety risks.
By 2019, BD was tracking more than 160 software issues, increasing to more than 200 by August. More than 25 were categorized by BD experts as presenting the greatest potential harm to patients. In October 2019, the FDA warned BD that continuing to sell Alaris with unresolved defects and safety problems was not acceptable.
The SEC found that BD nevertheless gave investors the impression that the Alaris problems involved routine software improvements and that the interruption in sales would be temporary. The company did not adequately disclose the possibility that it might be unable to resume normal sales until it received new FDA clearance.
BD also failed to properly account for the expected cost of fixing Alaris. By November 2019, the company estimated remediation costs at approximately $59 million but did not record those costs as required, resulting in an overstatement of its reported financial results.
In January 2020, BD resumed shipments but later stopped them again after further discussions with the FDA. On February 6, the company told investors that new FDA clearance would be required and lowered its financial guidance. BDX shares fell approximately 12% that day.
The SEC later found that BD’s disclosure and accounting failures harmed investors. BD paid a $175 million civil penalty, which now makes up the SEC Fair Fund available for distribution to eligible harmed investors.
What Can Investors Expect Now?
The SEC established a $175 million Fair Fund for investors harmed by Becton Dickinson’s misleading statements about regulatory and safety risks affecting its Alaris infusion pump and its improper accounting for remediation costs.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.
Frequently Asked Questions
Investors who purchased or acquired Becton, Dickinson and Company (BDX) common stock between February 5, 2019, and February 5, 2020, and suffered eligible losses may qualify for compensation from the $175 million SEC Fair Fund.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.